AU2022267110A1 - Composition for ameliorating or suppressing decline of kidney functions - Google Patents
Composition for ameliorating or suppressing decline of kidney functions Download PDFInfo
- Publication number
- AU2022267110A1 AU2022267110A1 AU2022267110A AU2022267110A AU2022267110A1 AU 2022267110 A1 AU2022267110 A1 AU 2022267110A1 AU 2022267110 A AU2022267110 A AU 2022267110A AU 2022267110 A AU2022267110 A AU 2022267110A AU 2022267110 A1 AU2022267110 A1 AU 2022267110A1
- Authority
- AU
- Australia
- Prior art keywords
- composition
- renal function
- ergothioneine
- salt
- level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003907 kidney function Effects 0.000 title claims abstract description 110
- 239000000203 mixture Substances 0.000 title claims abstract description 95
- 230000007423 decrease Effects 0.000 title claims abstract description 57
- SSISHJJTAXXQAX-ZETCQYMHSA-N L-ergothioneine Chemical compound C[N+](C)(C)[C@H](C([O-])=O)CC1=CNC(=S)N1 SSISHJJTAXXQAX-ZETCQYMHSA-N 0.000 claims abstract description 82
- 150000003839 salts Chemical class 0.000 claims abstract description 59
- 238000000034 method Methods 0.000 claims abstract description 21
- 239000004480 active ingredient Substances 0.000 claims abstract description 5
- 235000013305 food Nutrition 0.000 claims description 72
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 56
- 239000008280 blood Substances 0.000 claims description 48
- 210000004369 blood Anatomy 0.000 claims description 48
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims description 32
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims description 32
- 229940116269 uric acid Drugs 0.000 claims description 32
- 229940109239 creatinine Drugs 0.000 claims description 28
- 235000013361 beverage Nutrition 0.000 claims description 18
- 230000009471 action Effects 0.000 claims description 16
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 claims description 8
- 238000012360 testing method Methods 0.000 description 45
- 239000000825 pharmaceutical preparation Substances 0.000 description 26
- 229940127557 pharmaceutical product Drugs 0.000 description 26
- 230000008859 change Effects 0.000 description 18
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 241000282412 Homo Species 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 239000002775 capsule Substances 0.000 description 6
- 229940093497 ergothioneine Drugs 0.000 description 6
- 230000008085 renal dysfunction Effects 0.000 description 6
- 230000037406 food intake Effects 0.000 description 5
- 208000037157 Azotemia Diseases 0.000 description 4
- 206010018364 Glomerulonephritis Diseases 0.000 description 4
- 201000005569 Gout Diseases 0.000 description 4
- 240000001462 Pleurotus ostreatus Species 0.000 description 4
- 235000001603 Pleurotus ostreatus Nutrition 0.000 description 4
- 208000001647 Renal Insufficiency Diseases 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- -1 inorganic acid salts Chemical class 0.000 description 4
- 201000006370 kidney failure Diseases 0.000 description 4
- 229930014626 natural product Natural products 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 208000009852 uremia Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 244000251953 Agaricus brunnescens Species 0.000 description 2
- 244000191482 Cantharellus cibarius Species 0.000 description 2
- 235000015722 Cantharellus cibarius Nutrition 0.000 description 2
- 240000008397 Ganoderma lucidum Species 0.000 description 2
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 2
- 240000000588 Hericium erinaceus Species 0.000 description 2
- 240000000599 Lentinula edodes Species 0.000 description 2
- 235000001715 Lentinula edodes Nutrition 0.000 description 2
- 240000002769 Morchella esculenta Species 0.000 description 2
- 235000002779 Morchella esculenta Nutrition 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000007910 chewable tablet Substances 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 244000045069 Agrocybe aegerita Species 0.000 description 1
- 235000008121 Agrocybe aegerita Nutrition 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241001489124 Boletus edulis Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 240000001080 Grifola frondosa Species 0.000 description 1
- 235000007710 Grifola frondosa Nutrition 0.000 description 1
- 235000007328 Hericium erinaceus Nutrition 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241001492261 Pleurotaceae Species 0.000 description 1
- 241000222350 Pleurotus Species 0.000 description 1
- 241000392443 Pleurotus citrinopileatus Species 0.000 description 1
- 235000007685 Pleurotus columbinus Nutrition 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 241000121220 Tricholoma matsutake Species 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The purpose of the present invention is to provide a composition for ameliorating or suppressing the decline of kidney functions and a method for ameliorating or suppressing the decline of kidney functions. The present invention pertains to a composition for ameliorating or suppressing the decline of kidney functions that contains L-ergothioneine or a salt thereof as an active ingredient.
Description
[0001] The present invention relates to a composition for reducing renal function decline or ameliorating renal function. The present invention also relates to, for example, a method of reducing renal function decline or ameliorating renal function.
[0002] The kidneys are organs that filter the blood to remove urine including waste, extra water, and the like from the body, thereby maintaining body fluid homeostasis. In medical checkups and the like, the condition of renal function is determined using the blood urea nitrogen (BUN) concentration (BUN level) and the like as indices. In countries such as Japan, recent excessive salt and excessive protein diet has increased the burden on the kidneys, causing renal function decline. Renal function is known to decline with aging.
[0003] Ergothioneine is an amino acid found in mushrooms and the like. L-ergothioneine is present in nature. According to Patent Literature 1, the peritesticular fat weight and the triglyceride (neutral fat) level in plasma were lower in mice orally administered with ergothioneine than in mice not orally administered with ergothioneine.
CITATION LIST - Patent Literature
[0004] Patent Literature 1: JP 2011-102286 A
SUMMARY OF INVENTION - Technical Problem
[0005] However, it has not been known that L-ergothioneine or a salt thereof has an action to reduce renal function decline or ameliorate renal function. Generally, renal dysfunction is irreversible with few subjective symptoms. Thus, there has been a demand for components effective in reducing renal function decline or ameliorating renal function and applicable to foods for specified health uses, foods with function claims, pharmaceutical products, and the like.
[0006] The present invention aims to provide a composition for reducing renal function decline or ameliorating renal function. The present invention also aims to provide a method of reducing renal function decline or ameliorating renal function.
- Solution to Problem
[0007] As a result of extensive studies to solve the problem described above, the present inventors found that L ergothioneine has an action to reduce renal function decline or ameliorate renal function.
[0008] Specifically, the present invention relates to, but is not limited to, a composition for reducing renal function decline or ameliorating renal function, a method of reducing renal function decline or ameliorating renal function, and the like described below. (1) A composition for reducing renal function decline or ameliorating renal function, the composition containing L ergothioneine or a salt thereof as an active ingredient. (2) The composition according to (1) above, wherein the composition has an action to suppress an increase in blood urea nitrogen (BUN) level or reduce blood urea nitrogen (BUN) level. (3) The composition according to (1) or (2) above, wherein the composition has an action to suppress an increase in blood uric acid level or reduce blood uric acid level. (4) The composition according to any one of (1) to (3) above, wherein the composition has an action to suppress an increase in blood creatinine level or reduce blood creatinine level. (5) The composition according to any one of (1) to (4) above, wherein the composition is an oral composition. (6) The composition according to any one of (1) to (5) above, wherein the composition is a food or beverage. (7) The composition according to any one of (1) to (6) above, wherein an amount of L-ergothioneine or a salt thereof in the composition per adult daily intake is 2 to 50 mg in terms of L-ergothioneine. (8) A method of reducing renal function decline or ameliorating renal function, the method including administering L-ergothioneine or a salt thereof to a subject. (9) Use of L-ergothioneine or a salt thereof for reducing renal function decline or ameliorating renal function.
- Advantageous Effects of Invention
[00091 The present invention can provide a composition for reducing renal function decline or ameliorating renal function. The present invention can provide a method of reducing renal function decline or ameliorating renal function.
[0010] FIG. 1 is a graph showing change in BUN level (A in BUN) of a test food group and a control food group. FIG. 2 is a graph showing change in blood uric acid level (A in uric acid) of the test food group and the control food group. FIG. 3 is a graph showing change in blood creatinine level (A in creatinine) of the test food group and the control food group.
[0011] The composition for reducing renal function decline or ameliorating renal function of the present invention contains L-ergothioneine or a salt thereof as an active ingredient. Hereinafter, the composition for reducing renal function decline or ameliorating renal function of the present invention is sometimes simply referred to as "the composition of the present invention".
[0012] L-ergothioneine is one of the amino acids. The salt of L-ergothioneine is not limited as long as it is a pharmacologically acceptable salt or a dietary acceptable salt, and it may be either an acid salt or a basic salt. Examples of the acid salt include inorganic acid salts such as hydrochloride, sulfate, nitrate, and phosphate, and organic acid salts such as acetate, citrate, maleate, malate, oxalate, lactate, succinate, fumarate, and propionate. Examples of the basic salt include alkali metal salts such as sodium salt and potassium salt, and alkaline earth metal salts such as calcium salt and magnesium salt.
[0013]
L-ergothioneine or a salt thereof that can be used may be a chemically synthesized product or a purified extract of a natural product. L-ergothioneine is abundantly present in golden/yellow oyster mushrooms (binomial name: Pleurotus cornucopiae var. citrinopileatus) belonging to the genus Pleurotus of the family Pleurotaceae. L-ergothioneine is also present in mushrooms such as common mushrooms (binomial name: Agaricus bisporus) including white mushroom, cremini mushroom, and portabella mushroom; grey oyster mushroom (binomial name: Pleurotus ostreatus), shiitake (binomial name: Lentinula edodes), hen-of-the-wood (binomial name: Grifola Frondosa), reishi mushroom (binomial name: Ganoderma lucidum), lion's mane mushroom (binomial name: Hericium erinaceus), Yanagi matsutake (binomial name: Agrocybe aegerita), girolle (binomial name: Cantharellus cibarius), porcini (binomial name: Boletus edulis), and common morel (binomial name: Morchella esculenta). When L-ergothioneine is obtained from a natural product, preferably, it is extracted from a golden/yellow oyster mushroom, for example. L ergothioneine or a salt thereof can also be produced by microbial fermentation. An extract containing L ergothioneine or a salt thereof produced by microbial fermentation or a purified product thereof may be used. L ergothioneine can be extracted and purified from natural products by known methods. L-ergothioneine or a salt thereof may be in an isolated form.
[0014] L-ergothioneine or a salt thereof is present in natural products and food and beverages, and it is a compound that has been consumed. Thus, continuous ingestion of L-ergothioneine or a salt thereof, for example, is less likely to cause problems in terms of safety.
[0015]
In the present invention, the expression "reducing renal function decline" encompasses maintaining renal function, delaying the progress of renal function decline, arresting renal function decline, and the like. The expression "ameliorating renal function" includes reduction (alleviation) in the degree of renal function decline, recovery of declined renal function, improvement in renal function, and the like. Recovery includes at least partial recovery.
[0016] Renal function can be evaluated by examining at least one (preferably all the three) selected from the group consisting of blood urea nitrogen (BUN) level, blood creatinine level, and blood uric acid level. The blood BUN level, blood creatinine level, and blood uric acid level are used as indices of renal function. A suppressed increase or a reduction in at least one of BUN level, blood creatinine level, and blood uric acid level (preferably, all of these levels) usually indicates that renal function decline is reduced or that renal function is ameliorated.
[0017] As described later in Examples, ingestion of L ergothioneine reduced blood urea nitrogen (BUN) level, blood creatinine level, and blood uric acid level, compared to no ingestion. L-ergothioneine or a salt thereof has an action to suppress an increase in BUN level or reduce BUN level, an action to suppress an increase in blood uric acid level or reduce blood uric acid level, and an action to suppress an increase in blood creatinine level or reduce blood creatinine level. Thus, L-ergothioneine or a salt thereof has an action to reduce renal function decline or an action to ameliorate renal function. L-ergothioneine or a salt thereof can be used as an active ingredient to reduce renal function decline or ameliorate renal function.
[0018]
Preferably, the composition of the present invention has an action to suppress an increase in at least one selected from the group consisting of blood urea nitrogen (BUN) level, blood uric acid level, and blood creatinine level or reduce at least one selected from the above group. More preferably, the composition of the present invention has an action to suppress an increase in blood BUN level, blood uric acid level, and blood creatinine level or reduce blood BUN level, blood uric acid level, and blood creatinine level.
[0019] In one embodiment, the composition of the present invention can be preferably used as a composition for reducing renal function decline or ameliorating renal function in humans. The composition of the present invention can be used to, for example, prevent or ameliorate a condition or disease caused by renal function decline. Examples of the condition or disease caused by renal function decline include renal dysfunction, kidney failure, glomerulonephritis, uremia, gout, and uric acid stones. In one embodiment, the composition of the present invention can be used to prevent or ameliorate renal dysfunction, kidney failure, glomerulonephritis, uremia, gout, or uric acid stones. Preventing a condition or disease encompasses preventing the onset, delaying the onset, reducing the incidence rate, reducing the onset risk, and the like. Ameliorating a condition or disease encompasses helping a subject recover from a condition or disease, alleviating a symptom of a condition or disease, favorably changing a symptom of a condition or disease, delaying or preventing the progress of a condition or disease, and the like.
[0020] The composition of the present invention is applicable for therapeutic use (medical use) and non- therapeutic use (non-medical use). The term "non therapeutic" is a concept that does not include medical activities, i.e., a concept that does not include methods of surgery, therapy, or diagnosis of humans. The composition for reducing renal function decline or ameliorating renal function of the present invention can be provided as an agent or the like, for example, but it is not limited thereto. The agent can be directly provided as a composition or can be provided as a composition containing the agent. In one embodiment, the composition for reducing renal function decline or ameliorating renal function of the present invention can also be referred to as an agent for reducing renal function decline or ameliorating renal function. In order to sufficiently obtain the effect of the present invention, preferably, the composition of the present invention is an oral composition. The oral composition may be a food or beverage, an oral pharmaceutical product, an oral quasi-pharmaceutical product, or feed, preferably a food or beverage or an oral pharmaceutical product, more preferably a food or beverage.
[0021] The composition of the present invention may contain optional additives and optional components in addition to L-ergothioneine or a salt thereof, as long as the effect of the present invention is not impaired. Such additives and components can be selected according to the composition form or the like. Those that can be generally used in food and beverages, pharmaceutical products, quasi pharmaceutical products, feed, and the like can be used. When the composition of the present invention is provided as a food or beverage, a pharmaceutical product, a quasi pharmaceutical product, feed, or the like, the production method is not limited, and any common method can be used for production.
[0022] For example, when the composition of the present invention is provided as a food or beverage, various types of food or beverages can be provided by adding a component usable in food and beverages (e.g., a food material or an optional food additive) to L-ergothioneine or a salt thereof. Non-limiting examples of the food or beverage include general food and beverages, health foods, health beverages, foods with function claims, foods for specified health uses, dietary supplements, and food and beverages for the sick. The health foods, foods with function claims, foods for specified health uses, dietary supplements, and the like can be used, for example, in various forms of preparations such as fine granules, tablets, granules, powders, capsules, chewable tablets, syrups, liquids, and liquid foods.
[0023] When the composition of the present invention is provided as a pharmaceutical product or a quasi pharmaceutical product, for example, a pharmacologically acceptable carrier, an optional additive, or the like can be added to L-ergothioneine or a salt thereof to provide pharmaceutical products or quasi-pharmaceutical products in various dosage forms. Such a carrier, an additive, or the like may be any pharmacologically acceptable one that can be used in pharmaceutical products or quasi-pharmaceutical products. Examples thereof include excipients, binders, disintegrants, lubricants, antioxidants, and colorants. One or more of these can be used. The administration form of pharmaceutical products or quasi-pharmaceutical products may be oral or parenteral. Oral administration is preferred in order to obtain the effect of the present invention more sufficiently. When the composition of the present invention is provided as a pharmaceutical product or a quasi-pharmaceutical product, preferably, it is an oral pharmaceutical product or an oral quasi-pharmaceutical product. Examples of dosage forms for oral administration include liquids, tablets, powders, fine granules, granules, sugar-coated tablets, capsules, suspensions, emulsions, and chewable tablets. Examples of dosage forms for parenteral administration include injection and infusion. The pharmaceutical product and the quasi-pharmaceutical product may be for non-human animals.
[0024] When the composition of the present invention is provided as feed, L-ergothioneine or a salt thereof is simply added to feed. The feed includes feed additives. Examples of the feed include livestock feed for animals such as cows, pigs, chickens, sheep, and horses; feed for small animals such as rabbits, rats, and mice; and pet food for animals such as dogs, cats, and birds.
[0025] The amount of L-ergothioneine or a salt thereof in the composition of the present invention is not limited and can be set according to the composition form and the like. The amount of L-ergothioneine or a salt thereof in the composition of the present invention is preferably 0.0001 wt% or more, more preferably 0.001 wt% or more and is preferably 90 wt% or less, more preferably 50 wt% or less in terms of L-ergothioneine, for example. In one embodiment, the amount of L-ergothioneine or a salt thereof in the composition is preferably 0.0001 to 90 wt%, more preferably 0.001 to 50 wt% in terms of L-ergothioneine. In one embodiment, when the composition of the present invention is provided as a food or beverage, a pharmaceutical product, a quasi-pharmaceutical product, feed, or the like, preferably, the amount of L ergothioneine or a salt thereof is in the above ranges. In the case of L-ergothioneine, the expression "the amount in terms of L-ergothioneine" or a similar expression refers to the amount of L-ergothioneine. In the case of a salt of L-ergothioneine, the expression refers to a value obtained by multiplying the molar number of the salt by the molecular weight of L-ergothioneine.
[0026] The composition of the present invention can be fed or administered by a method appropriate to the composition form. In order to more sufficiently obtain the effect of the present invention, preferably, the composition of the present invention is orally fed (orally administered). The intake (administration amount) of the composition of the present invention is not limited as long as it is an amount that provides an effect of reducing renal function decline or ameliorating renal function. The intake may be appropriately set according to the administration form, administration method, body weight of a subject, and the like.
[0027] In one embodiment, when orally feeding or administering the composition of the present invention to a human (adult) as a subject, the intake of L-ergothioneine or a salt thereof in terms of L-ergothioneine per day is preferably 2 mg or more, more preferably 5 mg or more, still more preferably 10 mg or more, and is preferably 50 mg or less, more preferably 25 mg or less, still more preferably 20 mg or less. In one embodiment, when orally feeding or administering to a human (adult) as a subject, the intake of L-ergothioneine or a salt thereof in terms of L-ergothioneine per day is preferably 2 to 50 mg, more preferably 5 to 25 mg, still more preferably 5 to 20 mg, particularly preferably 10 to 20 mg. Preferably, the above amount of the composition is fed or administered in one or more portions per day, for example, in one portion or several portions (for example, two or three portions) per day. In one embodiment of the present invention, the composition of the present invention may be an oral composition for feeding or administering the above amount of L-ergothioneine or a salt thereof per 60 kg body weight per day to a human. In one embodiment, when the composition of the present invention is parenterally administered to a human (adult), the administration amount of L-ergothioneine or a salt thereof in terms of L-ergothioneine per day is, for example, preferably 2 to 50 mg, more preferably 5 to 25 mg, still more preferably 5 to 20 mg, particularly preferably 10 to 20 mg. In one embodiment, in the case of a human (adult), preferably, the above amount of L-ergothioneine or a salt thereof is fed or administered per 60 kg body weight per day.
[0028] In one embodiment, preferably, the amount of L ergothioneine or a salt thereof in the composition of the present invention per adult daily intake is 2 to 50 mg in terms of L-ergothioneine. The amount of L-ergothioneine or a salt thereof in the composition of the present invention per adult daily intake is more preferably 5 to 25 mg, still more preferably 5 to 20 mg, particularly preferably 10 to 20 mg in terms of L-ergothioneine.
[0029] Continuous feeding or administration of L ergothioneine or a salt thereof is likely to result in a higher effect of reducing renal function decline or ameliorating renal function. Thus, in a preferred embodiment, the composition of the present invention is continuously fed or administered. In one embodiment of the present invention, the composition of the present invention is continuously fed or administered preferably for at least one week, more preferably for at least two weeks.
[0030]
The composition of the present invention may be fed or administered to any subject (subject to administration). The subject is preferably a human or non-human mammal, more preferably a human. The composition of the present invention may be fed or administered to a subject needing or wanting to reduce renal function decline or ameliorate renal function. Examples of the subject to administration include humans needing or wanting to prevent or ameliorate a condition or disease caused by renal function decline (e.g., renal dysfunction, kidney failure, glomerulonephritis, uremia, gout, uric acid stones, and the like). In one embodiment, the subject to administration may be a subject with a condition or disease caused by renal function decline. In one embodiment, the subject to administration of the composition of the present invention may be a healthy person. The composition of the present invention can also be used on a healthy person, for example, for purposes such as preventing a condition or disease caused by renal function decline.
[0031] The composition of the present invention may be labeled with a function claim based on a reduction in renal function decline or amelioration of renal function. For example, the composition of the present invention may be labeled with one or more function claims such as preventingg renal dysfunction", "ameliorating renal function", and "preventing renal disease". In one embodiment of the present invention, preferably, the composition of the present invention is a food or beverage labeled with such a function claim. The label may be one indicating use of the composition for obtaining the function. The label may be directly attached to the composition or may be attached to a container or a package of the composition.
[0032] The present invention encompasses the following method and use: a method of reducing renal function decline or ameliorating renal function, the method including feeding or administering L-ergothioneine or a salt thereof to a subject; and use of L-ergothioneine or a salt thereof for reducing renal function decline or ameliorating renal function. Feeding or administering L-ergothioneine or a salt thereof to a subject can reduce renal function decline or ameliorate renal function. Preferably, L-ergothioneine or a salt thereof is orally fed or administered. The method may be therapeutic or non-therapeutic. The use may be therapeutic or non-therapeutic.
[0033] In the method and use, L-ergothioneine or a salt thereof, preferred embodiments thereof, and the like are as described above for the composition for reducing renal function decline or ameliorating renal function of the present invention. In the method and use, preferably, L ergothioneine or a salt thereof is fed or administered to a subject one or more times per day, for example, one to several times (e.g., two to three times) per day. The use is preferably for humans or non-human mammals, more preferably for humans. In one embodiment, L-ergothioneine or a salt thereof can be used to prevent or ameliorate renal dysfunction, kidney failure, glomerulonephritis, uremia, gout, or uric acid stones, for example, by reducing renal function decline or ameliorating renal function.
[0034] In the method and use, L-ergothioneine or a salt thereof is simply used in an amount (effective amount) that provides the effect of reducing renal function decline or ameliorating renal function. L-ergothioneine or a salt thereof, preferred administration amounts thereof, preferred subjects to administration, and the like are as described above for the composition for reducing renal function decline or ameliorating renal function of the present invention. L-ergothioneine or a salt thereof may be directly fed or administered or may be fed or administered as a composition containing L-ergothioneine or a salt thereof. For example, the composition of the present invention may be fed or administered.
[00351 L-ergothioneine or a salt thereof can be used to produce a food or beverage, a pharmaceutical product, a quasi-pharmaceutical product, feed, or the like for use in reducing renal function decline or ameliorating renal function. In one embodiment, the present invention also encompasses use of L-ergothioneine or a salt thereof for producing a composition for reducing renal function decline or ameliorating renal function. The present invention also encompasses L ergothioneine or a salt thereof for use in reducing renal function decline or ameliorating renal function.
[00361 The present invention is described in further detail below with reference to examples, but the scope of the present invention is not limited thereto.
[0037] <Example 1> (Study on evaluation of blood renal function markers in humans) In order to evaluate the influence of supplements containing ergothioneine on blood renal function marker levels in humans, a placebo-controlled, randomized, double blind, parallel-group study was conducted on subjects including male and female adults (46 subjects in a test food group; 46 subjects in a control food group; 92 subjects in total). In this study, one capsule containing 20 mg ergothioneine (test food) or one capsule not containing ergothioneine (control food) was fed per day for four weeks. Blood renal function marker levels of each subject were measured for pre-testing before starting the study (before starting ingestion of the test food or control food). After ingestion of the test food or control food for four weeks, blood renal function marker levels of each subject were measured again (testing on week 4). Renal function markers used for measurement were BUN, uric acid, and creatinine.
[00381 (Food for evaluation) Two types of food for evaluation, which were indistinguishable in appearance, flavor, and the like, were used. • Test food: capsule containing a test substance (20 mg L ergothioneine) • Control food: capsule containing no test substance Each type of food for evaluation contained raw materials such as dextrin, hydroxypropyl cellulose, carrageenan, potassium chloride, and titanium oxide, in addition to the test substance. The control food was produced using the same raw materials used in the test food, except that the test substance (L-ergothioneine) was not added.
[00391 (BUN) For each subject, the BUN level measured at the time of pre-testing was subtracted from the BUN level measured at the time of testing on week 4 ((level measured at the time of testing on week 4) - (level measured at the time of pre-testing)) to determine A in level (the amount of change in BUN level) (mg/dL). The average A in level of the subjects in the test food group was regarded as the amount of change in BUN (A in BUN) of the test food group. The average A in level of the subjects in the control food group was regarded as the amount of change in BUN (A in BUN) of the control food group. The amount of change in BUN level at the time of pre-testing was set to 0. FIG. 1 shows the results.
[0040] FIG. 1 is a graph showing change in BUN level (A in BUN) of the test food group and the control food group. In FIG. 1, FIG. 2, and FIG. 3, U (black square) indicates the test food group, and E (white square) indicates the control food group. In FIG. 1, FIG. 2, and FIG. 3, the unit for the vertical axis is mg/dL. On the horizontal axis, "Pre" indicates at the time of pre-testing, and "On week 4" indicates at the time of testing on week 4. According to the results, the BUN level was reduced more in the test food group than in the control food group.
[0041] (Uric acid level) For each subject, the uric acid level measured at the time of pre-testing was subtracted from the uric acid level measured at the time of testing on week 4 ((level measured at the time of testing on week 4) - (level measured at the time of pre-testing)) to determine A in level (the amount of change in uric acid level) (mg/dL). The average A in level of the subjects in the test food group was regarded as the amount of change in uric acid level (A in uric acid) of the test food group. The average A in level of the subjects in the control food group was regarded as the amount of change in uric acid level (A in uric acid) of the control food group. The amount of change in uric acid level at the time of pre-testing was set to 0. FIG. 2 shows the results.
[0042] FIG. 2 is a graph showing change in blood uric acid level (A in uric acid) of the test food group and the control food group. According to the results, the blood uric acid level was reduced more in the test food group than in the control food group.
[0043] (Creatinine level) For each subject, the creatinine level measured at the time of pre-testing was subtracted from the creatinine level measured at the time of testing on week 4 ((level measured at the time of testing on week 4) - (level measured at the time of pre-testing)) to determine A in level (the amount of change in creatinine level) (mg/dL). The average A in level of the subjects in the test food group was regarded as the amount of change in creatinine level (A in creatinine) of the test food group. The average A in level of the subjects in the control food group was regarded as the amount of change in creatinine level (A in creatinine) of the control food group. The amount of change in creatinine level at the time of pre testing was set to 0. FIG. 3 shows the results.
[0044] FIG. 3 is a graph showing change in blood creatinine level (A in creatinine) of the test food group and the control food group. According to the results, the increase in blood creatinine level was suppressed more in the test food group than in the control food group.
[0045] The above results show that L-ergothioneine or a salt thereof has an action to reduce renal function decline or ameliorate renal function.
Claims (9)
- Claim 1. A composition for reducing renal function decline or ameliorating renal function, the composition comprising L-ergothioneine or a salt thereof as an active ingredient.
- Claim 2. The composition according to claim 1, wherein the composition has an action to suppress an increase in blood urea nitrogen (BUN) level or reduce blood urea nitrogen (BUN) level.
- Claim 3. The composition according to claim 1 or 2, wherein the composition has an action to suppress an increase in blood uric acid level or reduce blood uric acid level.
- Claim 4. The composition according to any one of claims 1 to 3, wherein the composition has an action to suppress an increase in blood creatinine level or reduce blood creatinine level.
- Claim 5. The composition according to any one of claims 1 to 4, wherein the composition is an oral composition.
- Claim 6. The composition according to any one of claims 1 to 5, wherein the composition is a food or beverage.
- Claim 7. The composition according to any one of claims 1 to 6, wherein an amount of L-ergothioneine or a salt thereof in the composition per adult daily intake is 2 to 50 mg in terms of L-ergothioneine.
- Claim 8. A method of reducing renal function decline or ameliorating renal function, the method comprising administering L-ergothioneine or a salt thereof to a subject.
- Claim 9. Use of L-ergothioneine or a salt thereof for reducing renal function decline or ameliorating renal function.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021074321 | 2021-04-26 | ||
| JP2021-074321 | 2021-04-26 | ||
| PCT/JP2022/014246 WO2022230491A1 (en) | 2021-04-26 | 2022-03-25 | Composition for ameliorating or suppressing decline of kidney functions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022267110A1 true AU2022267110A1 (en) | 2023-10-05 |
Family
ID=83847930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022267110A Pending AU2022267110A1 (en) | 2021-04-26 | 2022-03-25 | Composition for ameliorating or suppressing decline of kidney functions |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP4331581A1 (en) |
| JP (1) | JPWO2022230491A1 (en) |
| CN (1) | CN117241796A (en) |
| AU (1) | AU2022267110A1 (en) |
| TW (1) | TW202308613A (en) |
| WO (1) | WO2022230491A1 (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5658479B2 (en) | 2009-04-27 | 2015-01-28 | 株式会社岩出菌学研究所 | Composition showing activity such as fat reduction |
| KR20220041883A (en) * | 2019-07-26 | 2022-04-01 | 펀다시오 인스티튜트 드’인베스티가시오 바이오메티칼 드 벨리비티게 (아이디벨) | Ergothioneine, S-methyl-ergothioneine and uses thereof |
| CN113308378B (en) * | 2020-02-26 | 2022-11-29 | 华南农业大学 | Ganoderma lucidum strain for high-yield ergothioneine and application thereof |
-
2022
- 2022-03-25 WO PCT/JP2022/014246 patent/WO2022230491A1/en active Application Filing
- 2022-03-25 JP JP2023517170A patent/JPWO2022230491A1/ja active Pending
- 2022-03-25 EP EP22795409.6A patent/EP4331581A1/en active Pending
- 2022-03-25 AU AU2022267110A patent/AU2022267110A1/en active Pending
- 2022-03-25 CN CN202280030906.0A patent/CN117241796A/en active Pending
- 2022-04-21 TW TW111115150A patent/TW202308613A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN117241796A (en) | 2023-12-15 |
| JPWO2022230491A1 (en) | 2022-11-03 |
| WO2022230491A1 (en) | 2022-11-03 |
| EP4331581A1 (en) | 2024-03-06 |
| TW202308613A (en) | 2023-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20060159698A1 (en) | Drug product for intestinal disease | |
| EP4331580A1 (en) | Composition for increasing red blood cells and/or hemoglobin | |
| US20240173298A1 (en) | Composition for ameliorating or suppressing decline of kidney functions | |
| EP4331581A1 (en) | Composition for ameliorating or suppressing decline of kidney functions | |
| EP4331671A1 (en) | Anti-anxiety composition | |
| EP4052704A1 (en) | Composition for sleep improvement comprising ergothioneine or salt thereof | |
| JPH0638708A (en) | Sodium absorption inhibitor, sodium, absorption inhibitor-containing food for preventing hypertension and therapeutic agent for hypertension | |
| EP4331680A1 (en) | Composition for increasing leukocytes and/or basophils | |
| EP4331665A1 (en) | Composition for promoting lipolysis | |
| US20240156785A1 (en) | Composition for improving blood cholesterol level | |
| WO2023090260A1 (en) | Composition for inhibiting histamine-n-methyltransferase | |
| JP2024069498A (en) | Composition for improving sleep containing ergothioneine or its salt | |
| TW202339725A (en) | Oral composition and method for suppressing bitterness derived from ergothioneine | |
| WO2024029393A1 (en) | Oral composition, and method for suppressing bitterness derived from ergothioneine or salt thereof and odor derived from milk-derived ceramide-containing material | |
| TW202342005A (en) | Oral composition, and method for suppressing bitterness derived from ergothioneine or salt thereof and odor derived from eicosapentaenoic acid | |
| TW202342004A (en) | Oral composition, and method for suppressing bitterness derived from ergothioneine or salt thereof and odor derived from docosahexaenoic acid | |
| TW202342008A (en) | oral composition, and method for suppressing bitterness derived from ergothioneine and odor derived from cereal oil or [gamma]-oryzanol | |
| TW202415371A (en) | Oral composition and method for suppressing bitter taste from ergothioneine or its salt | |
| TW202412842A (en) | Oral composition and method for suppressing bitter taste derived from ergothioneine and off-flavor derived from glucosamine compounds | |
| TW202412780A (en) | Oral composition and method for suppressing bitter taste derived from ergothioneine or its salts or odor derived from raw materials containing ceramide derived from milk |